China released the 2022 NDRL list, Chinese pharma benefited from the list

Updated: Dec 8, 2021

China has released the 2021 Drug catalog, which included 2,860 drugs, out of which 1,486 drugs are Western drugs.

Reuters reported a nearly 60% price cut for 67 products. These products include Lilly's Taltz and Janssen's Darzalex.

BeiGene's tislelizumab, Jiangsu Hengrui Medicine's camrelizumab, and Junshi Biosciences' toripalimab slashed prices by 80% to get included in the NDRL.


Also read: Top 10 pharma companies by revenues in 2020


InnoCare's orelabrutinib was included in the list for treating r/r chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL)

BeiGene's tislelizumab is included for patients with

  • non-squamous non-small cell lung cancer (NSCLC) as first-line therapy in combination with pemetrexed and platinum chemotherapy for patients (EGFR negative and ALK-negative cancers)

  • hepatocellular carcinoma previously treated with systemic therapy

  • urothelial carcinoma with PD-L1 high expression

  • Hodgkin's lymphoma (cHL) was treated with two systemic treatments previously

Brukinsa is included for treating Waldenström's macroglobulinemia (WM), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL). Pamiparib is included in NDRL for treating ovarian, fallopian tube, or primary peritoneal cancer.

Also read: China healthcare system


RemGen's telitacicept for systemic lupus erythematosus and disitamab vedotin for gastric cancer is included in NDRL

Asclevir (ravidasvir)/ Ganovo (danoprevir) regimen was included for treating HCV patients.

The list can be available from here:

http://www.nhsa.gov.cn/art/2021/12/3/art_37_7429.html




0 comments

Recent Posts

See All